FLAG-IDA is given as induction chemotherapy to eliminate leukemia cells from the body and to decrease symptoms from AML, such as bleeding, bruising, and recurrent infections. It may be given with the goal of cure or to put the leukemia in remission so a …

Nov 18, 2024 · In this context, fludarabine, AraC, G-CSF, and idarubicin (FLAG-Ida) has previously been reported to be effective salvage therapy for younger adults failing daunorubicin and AraC (DA) induction, 2 and is frequently applied in the setting of refractory disease. 3 Furthermore, in the MRC AML15 trial, which included 556 patients older than 60 ...

Nov 18, 2024 · first course of daunorubicin and AraC (DA; including 165 not in remission) were randomly assigned between up to two further courses of DA or in-tensified chemotherapy—eitherfludarabine, cytarabine, granulocyte colony-stimulating factor and idarubicin (FLAG-Ida) or DA with cladribine (DAC).

Nov 15, 2022 · FLAG-Ida Combined with Gemtuzumab Ozogamicin (GO) Improves Event Free Survival in Younger Patients with Newly Diagnosed Acute Myeloid Leukaemia (AML) and Shows an Overall Survival Benefit in NPM1 and FLT3 mutated Subgroups. Results from the UK NCRI AML19 Trial | Blood | American Society of Hematology.

We evaluated the efficacy and toxicity profiles of the combination of fludarabine, high-dose cytosine arabinoside (AraC), idarubicin, and granulocyte colony-stimulating factor (G-CSF) in refractory/relapsed acute myeloblastic leukemia (AML) patients.

Nov 18, 2024 · In this study of older patients with AML considered fit and with evidence of residual disease after first induction, chemotherapy intensification improved survival. DAC intensification was better tolerated than FLAG-Ida.

Forty-three consecutive patients with de novo and untreated non M3 AML aged 60 or less entered the study. The mean age of patients was 50 (range 15-60). The induction regimen (FLAG-Ida) included fludarabine (30 mg/sqm), Ara-C (2 g/sqm) on …

AraC is the most active agent in AML and demonstrates a steep dose-response curve. High dose araC (HiDAC) typically refers to doses ≥ 1000mg/m 2. Dose-escalation of araC to doses up to 1000 to 3000 mg/m 2 has been studied in induction and consolidation to take advantage of the dose-response. Several studies have demonstrated the benefit of ...

Nov 15, 2022 · Commonly used re-induction therapies are high dose cytarabine (HiDAC) and triple therapy consisting of fludarabine, cytarabine, idarubicin combined with granulocyte-colony stimulating factor (FLAG-IDA).

Mar 15, 2003 · We evaluated the efficacy and toxicity profiles of the combination of fludarabine, high-dose cytosine arabinoside (AraC), idarubicin, and granulocyte colony-stimulating factor (G-CSF) in refractory/relapsed acute myeloblastic leukemia (AML) patients.